Increasing molecular weight (kDa), increasing durability ABC ® Platform-based medicines have a high molecular weight which increases their ocular half-life compared to today’s intravitreal biologics Tarcocimab I 950 kDa Durability increases as molecular weight increases for intravitreal biologics KSI-501 I 1000 kDa Immediacy is achieved with lower molecular-weight intravitreal biologics Conjugated Portion of ABC ® Platform-based medicines* *Kodiak’s ABC platform-based medicines tarcocimab and KSI-501 combine unconjugated and conjugated protein in a single biologic 18